An Australian stem cell and regenerative medicine company

August 21, 2023

Cynata receives approval for trial in kidney transplant patients

Cynata has received regulatory approval from the Competent (regulatory) Authority in the Netherlands for a Phase 1 trial of CYP-001 in kidney transplant patients. Professor Rabelink, who is leading the trial, said it aims to alleviate anti-rejection drug side effects which would be of huge benefit to transplant patients as the side effects of immunosuppressants can be very devastating.

Read the full article here